Workshop on Intratumoral Immunomodulation • Nov. 7, 2019

Thursday, Nov. 7, 2019
8 a.m. 5 p.m.

Program Purpose

Immunotherapy treatments inherently rely on the presence of immune cells, both systemic and localized to the tumor microenvironment. Immunologically “hot” tumors, such as melanoma, have demonstrated enhanced responses to immunotherapy treatments; however, many tumors are “cold”, lacking the necessary immune components for a successful treatment. Many techniques, including radiotherapy, synthetic immunomodulators, oncolytic viruses, and certain systemic treatments, have been shown to manipulate the immune status of the treated tumor microenvironment, and even those tumor sites elsewhere in the body (abscopal effects). Such manipulations can increase the presence of desirable immune infiltrates and potentially lead to favorable treatment outcomes. In this workshop, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with their implications for current and forthcoming immunotherapy treatments.

Intended Audience

The intended audience for this program includes: basic scientists and clinical investigators from academic institutions, venture capital, industry, and regulatory agencies. Additional audiences benefiting from this program include clinicians, graduate students, and postdoctoral fellows involved in cancer research and its translation into clinical practice.

Workshop Organizers

  • Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
  • Adi Diab, MD – The University of Texas MD Anderson Cancer Center

Educational Objectives

  1. Describe the importance of the intratumoral immune environment and its implications for cancer treatment outcomes.
  2. Discuss the role and mechanisms of radiation treatments in intratumoral immunomodulation.
  3. Understand the effects of intratumoral synthetic immunomodulators and oncolytic viral therapies on the tumor microenvironment.
  4. Explain the impact that systemic combination treatments may have on local intratumoral immunomodulation as well as the impact localized treatment can have on the immune status of the rest of the body.

Program Schedule

Thursday, Nov. 7, 2019
8 a.m. Introduction

Session 1: Introduction to Intratumoral Immunomodulation
Time:
8:05 9:05 a.m.

8:05 a.m. Background

8:25 a.m. Cold vs. Hot Tumors

8:45 a.m. Target Cells

Session 2: Modes of Delivery
Time: 9:05 10:25 a.m.

9:05 a.m. Introduction to Intratumoral Therapy

9:20 a.m. Modes of Intratumoral Injections: Complexities and Approaches

9:45 a.m. Role of Radiation in STING Activation

10:05 a.m. SBRT and Immune Activation

Session 3: Intratumoral Synthetic Modulators
Time 10:40 a.m. 12 p.m.

10:40 a.m. TLR3

11 a.m. TLR9

11:20 a.m TLR7/8

11:40 a.m. STING Pathways

Session 4: Intratumoral Oncolytic Modulators
Time: 1 2 p.m.
1 p.m. T-VEC

1:20 p.m. Newcastle Disease Virus Therapy in Cancer

1:40 p.m. Oncolytic Viruses

Session 5: Systemic Combinations
Time:
2 4:55 p.m.

2 p.m. Intratumoral Checkpoint Blockade Inhibition

2:20 p.m. Anti-Tumor Vaccines Platforms

3 p.m. CD40: A Target for Systemic Immune Modulation

3:20 p.m. Clinical Assessment of Intratumoral Immunomodulation

3:40 p.m. Regulatory Implications for Drug Development

4 p.m. Systemic Combinations Panel Discussion

4:55 p.m. Closing

​​​​​​​​​​​

Schedule At-a-Glance

Wednesday, Nov. 6
World Immunotherapy Council's 3rd Young Investigator Symposium  
Industry Program
Thursday, Nov. 7

Primer on Tumor Immunology and Cancer Immunotherapy™

Social Activity: 
Early Career Scientist Networking Reception

Workshop on Intratumoral Immunomodulation

Meet-the-Expert Lunch
Grant Writing Workshop
34th Annual Meeting
Friday, Nov. 8 34th Annual Meeting Social Activity:
Poster Reception
Saturday, Nov. 9
34th Annual Meeting Social Activities:
Award Ceremony
Poster Reception
The Checkpoints Band Party
Sunday, Nov. 10 34th Annual Meeting Hot Topic Symposium